Production (Stage)
AEON Biopharma, Inc.
AEON
$0.84
-$0.02-2.33%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -41.17% | -31.06% | -23.84% | 13.43% | 37.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.36% | -47.34% | -40.18% | -15.40% | 0.05% |
| Operating Income | 57.36% | 47.34% | 40.18% | 15.40% | -0.05% |
| Income Before Tax | 134.87% | 110.92% | 103.48% | -291.60% | -644.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 134.87% | 110.92% | 103.48% | -291.60% | -644.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 134.87% | 110.92% | 103.48% | -291.60% | -644.60% |
| EBIT | 57.36% | 47.34% | 40.18% | 15.40% | -0.05% |
| EBITDA | 57.46% | 47.43% | 40.24% | 15.44% | -0.02% |
| EPS Basic | 144.31% | 115.10% | 103.36% | -796.13% | -1,897.55% |
| Normalized Basic EPS | 92.41% | -75.83% | -67.46% | -484.34% | -540.88% |
| EPS Diluted | 144.23% | 114.97% | 103.30% | -796.13% | -1,889.01% |
| Normalized Diluted EPS | 92.42% | -75.80% | -67.46% | -484.34% | -540.88% |
| Average Basic Shares Outstanding | 48.07% | -58.54% | -67.96% | -68.73% | -50.72% |
| Average Diluted Shares Outstanding | 48.10% | -58.52% | -67.96% | -68.73% | -50.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |